Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -203.44% is 19% above its 5-year average of -250.52%, near the high end of its 5-year range (-2559.77%–482.54%).
18.27% above its 12-month average of -248.92%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -221.94%.
EBITDA MARGIN
-203.44%
EBITDA MARGIN AVG TTM
-248.92%
EBITDA MARGIN AVG 3Y
-136.33%
EBITDA MARGIN AVG 5Y
-250.52%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.27%
CURRENT VS 3Y AVG
-49.23%
CURRENT VS 5Y AVG
+18.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Celularity Inc.
Market Cap
$49.50M
EBITDA Margin
-203.44%
TTM Avg
-248.92%
3Y Avg
-136.33%
5Y Avg
-250.52%
Market Cap
$49.96M
EBITDA Margin
-10794.00%
TTM Avg
-9994.66%
3Y Avg
-8986.60%
5Y Avg
-8678.68%
Market Cap
$50.25M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.51M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$46.79M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$52.95M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $49.50M | -203.44% | -248.92% | -136.33% | -250.52% |
| biote Corp. (BTMD)vs › | $49.40M | 20.40% | 19.12% | 4.66% | 12.12% |
| Clene Inc. (CLNN)vs › | $49.96M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Apollomics, Inc. (APLM)vs › | $50.51M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | -0.99% | 4.72% | -25.09% | -32.37% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | -36.23% | -36.23% | -36.23% | -36.23% |
| ImageneBio Inc (IMA)vs › | $53.01M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
Gross Margin
79.6%
EBITDA Margin
-203.4%
Operating Margin
-230.9%
Net Margin
-375.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -221.94% |
| 2025-12-31 | -493.54% |
| 2025-09-30 | -208.82% |
| 2025-06-30 | -244.60% |
| 2025-03-31 | -75.72% |
| 2024-12-31 | -40.83% |
| 2024-09-30 | -103.63% |
| 2024-06-30 | -67.53% |
| 2024-03-31 | -35.56% |
| 2023-12-31 | 128.89% |
| 2023-09-30 | -2559.77% |
| 2023-06-30 | -1366.71% |
| 2023-03-31 | -1563.07% |
| 2022-12-31 | 482.54% |
| 2022-09-30 | -78.65% |
| 2022-06-30 | 171.98% |
| 2022-03-31 | -662.68% |
| 2021-12-31 | -254.22% |
| 2021-09-30 | 124.68% |
| 2021-06-30 | -1835.47% |
| 2021-03-31 | -1596.20% |
| 2020-12-31 | 397.41% |
| 2020-09-30 | -119.91% |
| 2020-06-30 | -3882.78% |
| 2020-03-31 | -459.08% |
| 2019-12-31 | -599.26% |
